Genedata Advances R&D Efficiency With New Unified Sample Management Solution
Genedata's new Sample Management solution addresses this challenge by offering a dedicated new module for managing the precise physical location of each sample across different groups and sites, down to the building, shelf, and container. This ensures accurate tracking of each sample, enabling compliant and efficient inventory control, sample storage, location, requesting, and distribution. By being directly integrated with the Genedata bioregistration engine, the content and history of all samples are accessible at any time, whether it is a protein, plasmid, cell line, or complex mixture.
What makes this solution unique is its seamless integration within the Genedata Biopharma Platform, including Genedata Biologics ® and Genedata Bioprocess ®. This allows sample location data to be automatically linked with all relevant contextual information and metadata such as batch records, molecule properties, genealogy, and assay or QC results. No other software on the market offers this level of connectivity and information traceability within a single, fully integrated platform. By eliminating the need for external inventory systems, system integration, or data synchronization, it provides a unified, reliable source of truth for all biological samples.
Developed in close collaboration with leading biopharma partners, the new module combines robustness with ease of use. It supports configurable inventory hierarchies tailored to diverse laboratory environments, downloadable storage views for collaboration, and container dashboards for placing and retrieving aliquots. Importantly, all sample inventory and ordering processes can be fully automated. With sample quantity tracking capabilities, it adds spatial awareness and operational control to further improve efficiency and reduce risk.
"Recognizing the limitations of existing inventory and sample management solutions, we set out to build a fully integrated module designed to transform laboratory logistics," said Othmar Pfannes, Ph.D., President of Genedata. "Our goal is to pave the way for fully automated workflows that bring new levels of efficiency and precision to R&D. With this module, customers can manage their samples and inventories with the same rigor they apply to molecule and cell line registration, ensuring complete traceability for every sample and streamlining the R&D workflow through a trusted central data source."
About Genedata
Genedata, a Danaher company, transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | YouTube
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at .
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
SOURCE Genedata

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Wallpaper Market Size, Industry Overview, Latest Insights And Forecast 2025-2033
- GCL Subsidiary, 2Game Digital, Partners With Kucoin Pay To Accept Secure Crypto Payments In Real Time
- North America Perms And Relaxants Market Size, Share And Growth Report 2025-2033
- Chaingpt Pad Unveils Buzz System: Turning Social Hype Into Token Allocation
- Invromining Expands Multi-Asset Mining Platform, Launches New AI-Driven Infrastructure
- Global Mobile Wallet Market Size Projected To Reach USD 701.0 Billion By 2033 CAGR Of 15.09%.
Comments
No comment